Neurodevelopmental Outcomes in HI
Apr 3, 2023
Unrecognized or inadequately treated hyperinsulinism (HI) poses a high risk of adverse neurodevelopmental outcomes due to the combined insult of hypoglycemia and lack of alternate brain fuels.
Experts from CHOP’s Allergy Program are recognized as global leaders in the management of allergic conditions and have helped formulate many of the national guidelines used by physicians around the world.
Apr 3, 2023
Unrecognized or inadequately treated hyperinsulinism (HI) poses a high risk of adverse neurodevelopmental outcomes due to the combined insult of hypoglycemia and lack of alternate brain fuels.
Apr 3, 2023
The Congenital Hyperinsulinism Center at Children’s Hospital of Philadelphia, with a high volume of approximately 80 congenital hyperinsulinism (HI) cases a year, sees a large share of unusual cases.
Mar 31, 2023
Nancy Andrews shares her story about how her son’s multiple surgeries at CHOP inspired her family to give back.
Mar 31, 2023
The children of Vera Barksdale Johnson, CHOP’s first Emergency Department social worker, celebrate her joyful life and groundbreaking career through philanthropy.
Mar 31, 2023
CHOP’s First Episode Psychosis Program offers collaborative therapies that put youth on paths to better outcomes.
Mar 31, 2023
The Movement Disorders Program is one of the only programs of its kind in the country and provides life-changing results.
Mar 31, 2023
For 22 years, collaborative research at CHOP’s Biesecker Pediatric Liver Center has been changing the future for children with serious liver diseases.
Mar 31, 2023
Anne Ades, MD, MSEd, serves as Medical Co-Director of CHOP’s Center for Simulation, Advanced Education and Innovation, which uses computerized medical manikins to teach medical procedures. This is a day in her life.
Apr 4, 2023
Children’s Hospital of Philadelphia (CHOP) today announced that it has received more than $10 million in a series of gifts to fund critical neurofibromatosis research from the Gilbert Family Foundation, a private foundation established by Dan and Jennifer Gilbert to accelerate a cure for neurofibromatosis type 1 (NF1).
Apr 5, 2023
CHOP researchers have shown that adenovirus proteins use a process called phase separation to coordinate production of viral progeny, which could have broad implications.